Literature DB >> 10561097

Prognostic impact of telomerase activity in non-small cell lung cancers.

S Taga1, T Osaki, A Ohgami, H Imoto, K Yasumoto.   

Abstract

OBJECTIVE: To evaluate the clinical significance of telomerase activity, particularly in terms of prognostic impact, in non-small cell lung cancer (NSCLC). SUMMARY BACKGROUND DATA: Telomerase activity has been found in various tissues. The activation of telomerase is considered necessary for the immortalization of human tumor cells, including NSCLC.
METHODS: The authors studied 103 NSCLC specimens using a polymerase chain reaction based on a telomeric repeat amplification protocol assay.
RESULTS: Telomerase activity was detected in 85 (82.5%) of 103 NSCLC specimens but in none of the paired normal lung tissue specimens. More cases of positive telomerase activity were observed in the group with advanced disease and in the group with poorly differentiated tumors. Such factors as the mean age at surgery, sex, smoking, histologic type, and size of tumor extension did not correlate with the telomerase activity. The Kaplan-Meier survival curves in all patients with NSCLC demonstrated that patients with telomerase-positive tumors survived for a significantly shorter period than those with a telomerase-negative tumor (p = 0.0058). According to a multivariate analysis, telomerase activity was identified as an independent prognostic factor (RR = 8.62, p = 0.035).
CONCLUSIONS: Telomerase activity was one of the most important prognostic factors in patients with NSCLC, and its potential prognostic implication was independent of tumor stage.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10561097      PMCID: PMC1420927          DOI: 10.1097/00000658-199911000-00015

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  33 in total

Review 1.  Telomerases.

Authors:  E H Blackburn
Journal:  Annu Rev Biochem       Date:  1992       Impact factor: 23.643

2.  Telomere end-replication problem and cell aging.

Authors:  M Z Levy; R C Allsopp; A B Futcher; C W Greider; C B Harley
Journal:  J Mol Biol       Date:  1992-06-20       Impact factor: 5.469

3.  Origin of concatemeric T7 DNA.

Authors:  J D Watson
Journal:  Nat New Biol       Date:  1972-10-18

4.  Telomeres shorten during ageing of human fibroblasts.

Authors:  C B Harley; A B Futcher; C W Greider
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

5.  Correlating telomerase activity levels with human neuroblastoma outcomes.

Authors:  E Hiyama; K Hiyama; T Yokoyama; Y Matsuura; M A Piatyszek; J W Shay
Journal:  Nat Med       Date:  1995-03       Impact factor: 53.440

6.  Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication.

Authors:  T Mitsudomi; T Oyama; K Nishida; A Ogami; T Osaki; K Sugio; K Yasumoto; K Sugimachi; A F Gazdar
Journal:  Clin Cancer Res       Date:  1996-07       Impact factor: 12.531

7.  Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers.

Authors:  M Nishio; T Koshikawa; T Kuroishi; M Suyama; K Uchida; Y Takagi; O Washimi; T Sugiura; Y Ariyoshi; T Takahashi; R Ueda; T Takahashi
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

8.  Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer.

Authors:  T Mitsudomi; T Oyama; T Kusano; T Osaki; R Nakanishi; T Shirakusa
Journal:  J Natl Cancer Inst       Date:  1993-12-15       Impact factor: 13.506

9.  C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.

Authors:  J A Kern; R J Slebos; B Top; S Rodenhuis; D Lager; R A Robinson; D Weiner; D A Schwartz
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

10.  p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival.

Authors:  T Mitsudomi; T Oyama; K Nishida; A Ogami; T Osaki; R Nakanishi; K Sugio; K Yasumoto; K Sugimachi
Journal:  Ann Oncol       Date:  1995       Impact factor: 32.976

View more
  15 in total

1.  RNAi targeting of hTERT gene expression induces apoptosis and inhibits the proliferation of lung cancer cells.

Authors:  Linhu Ge; Wenlong Shao; Yangde Zhang; Yuan Qiu; Dong Cui; Donghai Huang; Zhansheng Deng
Journal:  Oncol Lett       Date:  2011-08-19       Impact factor: 2.967

2.  Prognostic significance of telomerase activity and some tumor markers in non-small cell lung cancer.

Authors:  Maha Hashim; Magda Sayed; Nervana Samy; Salah Elshazly
Journal:  Med Oncol       Date:  2010-02-10       Impact factor: 3.064

3.  Telomerase activity in periampullary tumors correlates with aggressive malignancy.

Authors:  J H Balcom; T Keck; A L Warshaw; B Antoniu; F Graeme-Cook; C Fernández-del Castillo
Journal:  Ann Surg       Date:  2001-09       Impact factor: 12.969

4.  Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. Prognostic implications.

Authors:  T Osaki; T Oyama; M Inoue; C D Gu; M Kodate; M Aikawa; T So; M Mizukami; T Mitsudomi; K Yasumoto
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-09

5.  Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.

Authors:  Espen Basmo Ellingsen; Elin Aamdal; Tormod Guren; Wolfgang Lilleby; Paal F Brunsvig; Sara M Mangsbo; Steinar Aamdal; Eivind Hovig; Nadia Mensali; Gustav Gaudernack; Else Marit Inderberg
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

6.  n-Butylidenephthalide induced apoptosis in the A549 human lung adenocarcinoma cell line by coupled down-regulation of AP-2alpha and telomerase activity.

Authors:  Chyou-wei Wei; Chai-ching Lin; Yung-luen Yu; Chai-yi Lin; Po-cheng Lin; Min-tze Wu; Cheng-jueng Chen; Wenliang Chang; Shinn-zong Lin; Yi-lin Sophia Chen; Horng-jyh Harn
Journal:  Acta Pharmacol Sin       Date:  2009-08-24       Impact factor: 6.150

7.  Telomerase detection in the diagnosis and prognosis of cancer.

Authors:  Eiso Hiyama; Keiko Hiyama
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

8.  NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.

Authors:  Vilde Drageset Haakensen; Anna K Nowak; Espen Basmo Ellingsen; Saima Jamil Farooqi; Maria Moksnes Bjaanæs; Henrik Horndalsveen; Tine Mcculloch; Oscar Grundberg; Susana M Cedres; Åslaug Helland
Journal:  J Transl Med       Date:  2021-05-31       Impact factor: 5.531

9.  Expression of VEGF, HGF, IL-6, IL-8, MMP-9, Telomerase in Peripheral Blood of Patients with Head and Neck Squamous Cell Carcinoma.

Authors:  Dae-Young Hong; Byung-Joo Lee; Jin-Choon Lee; Jin-Sik Choi; Soo-Geun Wang; Jung-Hoon Ro
Journal:  Clin Exp Otorhinolaryngol       Date:  2009-12-31       Impact factor: 3.372

Review 10.  Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential.

Authors:  Espen Basmo Ellingsen; Sara M Mangsbo; Eivind Hovig; Gustav Gaudernack
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.